Triple therapy shows promise for untreatable liver cancer

NCT ID NCT07081633

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is active but no longer recruiting. Researchers are measuring how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab, tremelimumab, and lenvatinib
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong: This is a phase 2 trial with only 114 participants and no comparison group, so results are preliminary. The drug combination may cause serious side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Research Site

Beijing, 100029, China
Research Site

Beijing, 100044, China
Research Site

Beijing, 100142, China
Research Site

Chengdu, 610078, China
Research Site

Chongqing, 400016, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510095, China
Research Site

Guangzhou, 510120, China
Research Site

Guangzhou, 510515, China
Research Site

Hangzhou, 310022, China
Research Site

Hefei, 230022, China
Research Site

Jinan, 250021, China
Research Site

Nanjing, 210009, China
Research Site

Nanjing, 210029, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200438, China
Research Site

Tianjin, 300060, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430030, China
Research Site

Xiamen, 361004, China
Research Site

Zhengzhou, 450052, China
Research Site

New Territories, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.